New neuroscience research identifies Glutamine Synthetase as the key enzyme driving postnatal brain maturation and neuronal ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, ...

Palvella Therapeutics Inc (PVLA) reports robust financial positioning and promising clinical developments, despite regulatory challenges.

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal ...

The human brain develops through an intricate balance of cellular growth, connectivity, and metabolism. A new study reveals ...

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific ...

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and ...

New data just threw a spicy curveball: natural compounds found in garlic extended lifespan by nearly twice as much as ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Celcuity Inc. (NASDAQ:CELC) Q4 2025 Earnings Call Transcript March 25, 2026 Celcuity Inc. beats earnings expectations. Reported EPS is $-0.97, expectations were $-1.06. Operator: Good afternoon, ...

Equity-Insider.com News Commentary -- Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing ...

UIC researchers have successfully repurposed an FDA-approved cancer drug, doxorubicin, to treat drug-resistant strains of ...